The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 20218623 |
68 |
Emerging targets in osteoporosis disease modification. |
Amgen |
| 18707091 |
14 |
Effect of cathepsin K inhibitors on bone resorption. |
Novartis Institutes For Biomedical Research |
| 16290936 |
69 |
Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors? |
Glaxosmithkline |
| 15896958 |
32 |
Acyclic cyanamide-based inhibitors of cathepsin K. |
Glaxosmithkline |
| 14741275 |
27 |
Design of small molecule ketoamide-based inhibitors of cathepsin K. |
Glaxosmithkline |
| 14736240 |
57 |
Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. |
Glaxosmithkline |
| 11311061 |
40 |
Azepanone-based inhibitors of human and rat cathepsin K. |
Glaxosmithkline |
| 1397049 |
24 |
NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. |
Novo Nordisk |
Search and Browse
